These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 1376910

  • 41. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
    Paz-Bouza JI, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
    [Abstract] [Full Text] [Related]

  • 42. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV.
    Pancreas; 1989 Feb; 4(5):521-8. PubMed ID: 2573055
    [Abstract] [Full Text] [Related]

  • 43. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A, Schally AV.
    Cancer Res; 1989 Apr 01; 49(7):1810-5. PubMed ID: 2564312
    [Abstract] [Full Text] [Related]

  • 44. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 2000 Oct 01; 83(7):906-13. PubMed ID: 10970693
    [Abstract] [Full Text] [Related]

  • 45. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1981 Oct 01; 78(10):6509-12. PubMed ID: 6458815
    [Abstract] [Full Text] [Related]

  • 46. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

  • 47. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 48. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
    de Quijada MG, Redding TW, Coy DH, Torres-Aleman I, Schally AV.
    Proc Natl Acad Sci U S A; 1983 Jun 01; 80(11):3485-8. PubMed ID: 6134284
    [Abstract] [Full Text] [Related]

  • 49. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I, Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1985 Feb 01; 82(4):1252-6. PubMed ID: 2858096
    [Abstract] [Full Text] [Related]

  • 50. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S.
    J Natl Cancer Inst; 1992 Dec 16; 84(24):1915-22. PubMed ID: 1460673
    [Abstract] [Full Text] [Related]

  • 51. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Groot K, Halmos G.
    Int J Cancer; 1993 May 08; 54(2):282-9. PubMed ID: 8387464
    [Abstract] [Full Text] [Related]

  • 52. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E, Bokser L, Comaru-Schally AM, Groot K, Schally AV.
    Proc Natl Acad Sci U S A; 1991 Feb 01; 88(3):844-8. PubMed ID: 1992476
    [Abstract] [Full Text] [Related]

  • 53. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1983 Mar 01; 80(5):1459-62. PubMed ID: 6219395
    [Abstract] [Full Text] [Related]

  • 54. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Kahan Z.
    Int J Oncol; 2000 Aug 01; 17(2):367-73. PubMed ID: 10891548
    [Abstract] [Full Text] [Related]

  • 55. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV, Redding TW, Comaru-Schally AM.
    Med Oncol Tumor Pharmacother; 1984 Aug 01; 1(2):109-18. PubMed ID: 6242477
    [Abstract] [Full Text] [Related]

  • 56. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1984 Jan 01; 81(1):248-52. PubMed ID: 6141560
    [Abstract] [Full Text] [Related]

  • 57. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
    Pinski J, Yano T, Groot K, Cai RZ, Radulovic S, Schally AV.
    Am J Physiol; 1992 Oct 01; 263(4 Pt 1):E712-7. PubMed ID: 1415689
    [Abstract] [Full Text] [Related]

  • 58. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
    Lamharzi N, Schally AV, Koppán M.
    Regul Pept; 1998 Oct 16; 77(1-3):185-92. PubMed ID: 9809814
    [Abstract] [Full Text] [Related]

  • 59. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV, Redding TW.
    Proc Natl Acad Sci U S A; 1985 Apr 16; 82(8):2498-502. PubMed ID: 3157990
    [Abstract] [Full Text] [Related]

  • 60. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.
    Prostate; 1999 Feb 01; 38(2):151-8. PubMed ID: 9973101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.